Home » Stocks » Five Prime Therapeutics

Five Prime Therapeutics, Inc. (FPRX)

Stock Price: $4.79 USD 0.03 (0.63%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
After-hours: $4.50 -0.29 (-6.05%) Aug 12, 7:55 PM

Stock Price Chart

Key Info

Market Cap 175.45M
Revenue (ttm) 18.03M
Net Income (ttm) -104.48M
Shares Out 36.63M
EPS (ttm) -2.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $4.79
Previous Close $4.76
Change ($) 0.03
Change (%) 0.63%
Day's Open 4.78
Day's Range 4.63 - 4.92
Day's Volume 222,894
52-Week Range 1.75 - 7.34

More Stats

Market Cap 175.45M
Enterprise Value 94.44M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 36.63M
Float 24.36M
EPS (basic) -2.97
EPS (diluted) -2.97
FCF / Share -2.46
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.59M
Short Ratio 4.23
Short % of Float 5.73%
Beta 2.92
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 9.73
PB Ratio 1.53
Revenue 18.03M
Operating Income -107.05M
Net Income -104.48M
Free Cash Flow -87.03M
Net Cash 81.01M
Net Cash / Share 2.21
Gross Margin -515.62%
Operating Margin -593.64%
Profit Margin -579.40%
FCF Margin -482.66%
ROA -27.73%
ROE -63.99%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 4
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.40*
(75.37% upside)
Low
5.00
Current: $4.79
High
11.00
Target: 8.40
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue14.8749.8739.5130.6938019.2313.799.9864.92-
Revenue Growth-70.17%26.22%28.73%-91.92%1874.94%39.45%38.14%-84.62%--
Gross Profit14.8749.8739.5130.6938019.2313.799.9864.92-
Operating Income-142-146-151-99.21287-37.57-29.42-27.8019.66-37.76
Net Income-137-140-150-65.70250-37.42-28.87-27.6019.71-13.46
Shares Outstanding34.9733.9827.9526.9625.6620.875.521.201.151.10
Earnings Per Share-3.92-4.13-5.38-2.449.23-1.79-5.23-23.050.72-12.22
Operating Cash Flow-114-123-112-79.7528915.27-25.33-18.4023.29-7.82
Capital Expenditures-1.78-11.33-4.93-2.96-2.43-1.64-0.81-0.74-0.97-3.31
Free Cash Flow-116-134-117-82.7128713.62-26.14-19.1322.32-11.14
Cash & Equivalents15827229442351714975.7238.0250.780.00
Total Debt49.61---------
Net Cash / Debt10827229442351714975.7238.0250.780.00
Assets22432234444854815681.7944.0958.58-
Liabilities73.6756.4078.8556.7111570.4323.77160149-
Book Value15026526539243385.2158.03-116-90.11-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Five Prime Therapeutics, Inc.
Country United States
Employees 87
CEO Tom Civik

Stock Information

Ticker Symbol FPRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FPRX
IPO Date September 18, 2013

Description

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.